Información del artículo
La nefropatía diabética es una complicación muy prevalente de la diabetes. Su abordaje exige un diagnóstico temprano, así como la reducción del impacto de los factores de riesgo implicados en su aparición y progresión: hiperglucemia, hipertensión, dislipemia y tabaquismo. Los objetivos que se deben conseguir son hemoglobina glucosilada < 7%, presión arterial < 130/80 mmHg, lipoproteínas de baja densidad < 100 mg/dl y abstinencia tabáquica. El abordaje de la hipertensión arterial exige el bloqueo del sistema renina-angiotensina, y el de la insuficiencia renal debe ser multidisciplinario y efectuarse de forma planificada, especialmente cuando se llega a la etapa terminal. En la actualidad se están estudiando diversas opciones terapéuticas, entre las que destacan la inhibición de la formación de productos avanzados de la glucosilación, el bloqueo de la proteincinasa C y el uso de glucosaminoglucanos.
Palabras clave:
Nefropatía diabética
Tratamiento
Hiperglucemia
Hipertensión
Tabaco
Diabetic nephropathy is a highly prevalent complication of diabetes, requiring early diagnosis and reduction of the impact of the risk factors involved in its pathogenesis and progression: hyperglycemia, hypertension, dyslipidemia and smoking. The targets are HbA1c < 7%, blood pressure < 130/80 mmHg, LDL-cholesterol < 100 mg/dl, and smoking cessation. Blood pressure control implies renin-angiotensin system blockade. A multidisciplinary and planned approach is mandatory in renal failure, especially in end-stage disease. Currently, several therapeutic options are being investigated, most importantly those involving inhibition of advanced glycosylated end products, protein kinase C blockade, and the use of glycosaminoglycans.
Key words:
Diabetic nephropathy
Treatment
Hyperglycemia
Hypertension
Smoking
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Esmatjes, C. Castell, T. González, R. Tresserras, G. Lloveras, The Catalan Nephropathy Study Group.
Epìdemiology of renal involvement in type II diabetics (NIDDM) in Catalonia.
Diab Res Clin Pract, 32 (1996), pp. 157-163
[2.]
E. Esmatjes, I. Goicolea, L. Cacho, P. De Pablos, R. Rodríguez, M. Roche, et al.
Nefropatía en la diabetes mellitus tipo II: prevalencia en España.
Avances en Diabetología, 13 (1997), pp. 29-35
[3.]
H.H. Parving, M. Mauer, E. Ritz.
Diabetic nephropathy.
The Kidney, 7th ed., pp. 1177-1818
[4.]
Diabetes Care and Research in Europe.
The Sant Vincent Declaration, 10 (1990), pp. 133-144
[5.]
B. Stengel, S. Billon, P.C.W. Van Dijk, K.J. Jager, F.W. Dekker, K. Simpson, et al.
Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999.
Nephrol Dial Transplant, 18 (2003), pp. 1824-1833
[6.]
Documento de consenso 2002 sobre pautas de detección, prevención y tratamiento de la nefropatía diabética en España. Nefrología. 2002;22: 521-30.
[7.]
The Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med, 329 (1993), pp. 977-986
[8.]
UK Prospective Diabetes Study Group.
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment a risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet, 352 (1998), pp. 837-853
[9.]
The DCCT/EDIC Research Group.
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
N Engl J Med, 342 (2000), pp. 381-389
[10.]
Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isasi, S. Motoyoshi, et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomised prospective 6-year study.
Diab Res Clin Pract, 28 (1995), pp. 103-117
[11.]
Standard of medical care in diabetes. Diabetes Care. 2005;28:S4-37.
[12.]
H.H. Parving, A.R. Anderesen, U.M. Smidt.
Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.
Lancet, 1 (1983), pp. 1175-1179
[13.]
G.L. Bakris, M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, R. Toto, et al.
Preserving renal function in adults with hypertension and diabetes: a consensus approach.
Am J Kidney Dis, 36 (2000), pp. 646-661
[14.]
J.R. Sowers, M. Epstein, E.D. Frohlich.
Diabetes, hypertension and cardiovascular disease. An update.
Hypertension, 37 (2001), pp. 1053
[15.]
American Diabetes Association.
Hypertension management in adults with diabetes (Position Statement).
Diabetes Care, 27 (2004), pp. S65-S67
[16.]
The Seventh Report of Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) Report. JAMA. 2002;289:2560-71
[17.]
M.A. Pohl, S. Blumenthal, D.J. Cordonier, F. De Alvaro, G. Deferrari, G. Eisner, et al.
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
J Am Soc Nephrol, 16 (2005), pp. 3027-3037
[18.]
M.E. Pavkov.
Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians.
Kidney Int, 70 (2006), pp. 1840-1846
[19.]
E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, For the Collaborative Group, et al.
Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due type-2 diabetes.
N Engl J Med, 345 (2001), pp. 851-860
[20.]
H.H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner, For de Irbesartan in patients with type 2 diabetes and microalbuminuria study group, et al.
N Engl J Med, 345 (2001), pp. 870-878
[21.]
B.M. Brenner, M.E. Cooper, D. De Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, For de RENAAL Study Investigators, et al.
Effects of losarta on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy.
N Engl J Med, 345 (2001), pp. 861-869
[22.]
K. Rossing, P.K. Christensen, B.R. Jensen, H.H. Parving.
Dual blockade of the renin angiotensin system in diabetic nephropathy. A randomized double-blind study.
Diabetes Care, 25 (2002), pp. 95-100
[23.]
P. Ruggenenti, A. Fassi, A.P. Ilieva, S. Bruno, I.P. Iliev, V. Brusegan, et al.
Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes.
N Engl J Med, 351 (2004), pp. 1941-1951
[24.]
A.S. Krolewski, J.H.G. Warram, A.R. Christlies.
Hypercholesterlemia a determinant of renal function loss and deaths in IDDM patients with nephropathy.
Kidney Int, 45 (1994), pp. S125-S131
[25.]
L.F. Fried, T.J. Orchard, B.L. Kasiske.
The effect of lipid reduction on renal isease progression. A meta-analysis.
Kidney Int, 59 (2001), pp. 260-269
[26.]
S.M. Haffner.
Dyslipidemia management in adults with diabetes.
Diabetes Care, 27 (2004), pp. S68-S71
[27.]
E. Ritz, H. Ogata, S.R. Orth.
Smoking: a factor promoting onset and progression of diabetic nephropathy.
Diabetes Metab, 26 (2000), pp. 54-63
[28.]
L.J. Scott, J.H. Warram, L.S. Hanna, L.M. Laffel, L. Ryan, A.S. Krolewski.
A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes.
Diabetes, 50 (2001), pp. 2842-2849
[29.]
W.K. Bolton, D.C. Cattran, M.E. Williams, S.G. Adler, G.B. Appel, K. Cartwright, et al.
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
Am J Nephrol, 24 (2004), pp. 32-40
[30.]
V.K. Pedchenko, S.V. Chetykrin, P. Chuang, A.J. Ham, M.A. Saleem, P.W. Mathieson, et al.
Mechanism of perturbation of integrin-mediated cellmartrix interactions by reactive carbonyl compounds and its implications for pathogenesis of diabetic nephropathy.
Diabetes, 54 (2005), pp. 2952-2960
[31.]
K.R. Tuttle, G.L. Backris, R.D. Toto, J.B. McGill, K. Hu, P.W. Anderson.
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
Diabetes Care, 28 (2005), pp. 2686-2690
[32.]
M.E. Williams.
New potential agents in trating diabetic kidney disease. The fourth act.
Drugs, 66 (2006), pp. 2287-2298
[33.]
Documento de consenso sobre pautas de detección y tratamiento de la nefropatía diabética en España. Avances en Diabetología. 1997;13:92-8.
Copyright © 2008. Sociedad Española de Endocrinología y Nutrición